Kymera Therapeutics Inc (KYMR)
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines designed to selectively degrade disease-causing proteins by using the body’s natural protein degradation pathways. The company’s pipeline includes KT-621, an oral STAT6 degrader in Phase 2b studies for inflammatory and allergic conditions such as atopic dermatitis, asthma, COPD, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and prurigo nodularis. It is also advancing KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases, and KT-485/SAR447971, an IRAK4 program in Phase II evaluation for immunology-inflammation disorders including hidradenitis suppurativa and atopic dermatitis. In addition, the company is developing a CDK2 program with potential applications in oncology, including breast cancer and other solid tumors. Kymera also has a strategic alliance with Sanofi focused on IRAK4 drug candidates outside oncology and immuno-oncology. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-KYMR
|
$85.04
|
-30.3% Downside
|
Overvalued
|
$138.64
|
13.6% Upside
|
Fair
|
Fair
|
0.0%
|
October 29, 2026
|
6.5x
|
93.2x
|
10.149 B
|
8.358 B
|
0.8%
|
79.4%
|
43.3
|
79.4%
|
